Purepac Free To Launch Neurontin Generic After Court Lifts Stay
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is not commenting on launch plans but previously said it would "commence commercial sales" if a court stay was lifted. Purepac said it would book revenues from its own gabapentin generic upon launch, but revenues received under an agreement with Teva would not be recorded until patent litigation with Pfizer is resolved.
You may also be interested in...
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
Purepac Approvals Re-Start With Glucophage XR Generic
FDA clearance of the company’s ANDA for metformin extended-release could bode well for Purepac’s chances that its generic version of Neurontin tablets will soon be approved. Approval of Purepac’s solid oral dose forms have been on hold due to manufacturing compliance issues.